| P50 | author | Ibrahim Yakoub-Agha | Q58191171 |
| | Herve Avet-Loiseau | Q61112732 |
| P2093 | author name string | B Mohty | |
| | M Mohty | |
| | P Moreau | |
| | J El-Cheikh | |
| P2860 | cites work | Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients | Q83179100 |
| | Relapsed multiple myeloma | Q83217330 |
| | Prolonged overall survival with second on-demand autologous transplant in multiple myeloma | Q83300465 |
| | Re-transplantation after bortezomib-based therapy | Q83319265 |
| | Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients | Q83444693 |
| | Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma | Q83608464 |
| | Toward deeper response in MM | Q83638825 |
| | Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials | Q84715517 |
| | Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment | Q85059501 |
| | Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group | Q85187993 |
| | Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial | Q28252396 |
| | Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial | Q30433139 |
| | Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma | Q33375805 |
| | Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression | Q33376149 |
| | Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma | Q33377526 |
| | Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. | Q33378895 |
| | High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program | Q33382175 |
| | Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). | Q33383048 |
| | Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma | Q33386405 |
| | Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients | Q33387698 |
| | Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. | Q33389075 |
| | The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function | Q33390284 |
| | Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). | Q33391803 |
| | Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study | Q33394281 |
| | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study | Q33394981 |
| | Repeat administration of high dose melphalan in relapsed myeloma | Q33492940 |
| | Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. | Q33632270 |
| | Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy. | Q33695612 |
| | Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial | Q33701381 |
| | Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy | Q34122646 |
| | Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma | Q34166574 |
| | The medical review article: state of the science | Q34191468 |
| | Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America | Q34585268 |
| | The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma | Q34595043 |
| | The use of novel agents in the treatment of relapsed and refractory multiple myeloma | Q35097319 |
| | Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma | Q35172445 |
| | Improved survival in multiple myeloma and the impact of novel therapies | Q36478461 |
| | Checklists for review articles | Q36887882 |
| | Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities | Q36941047 |
| | Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation | Q36969778 |
| | Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma | Q37007113 |
| | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma | Q37038414 |
| | An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma | Q37224994 |
| | Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. | Q37248327 |
| | Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma | Q37375819 |
| | Treatment of relapsed/refractory multiple myeloma | Q37457291 |
| | The role of complete response in multiple myeloma | Q37564828 |
| | CR represents an early index of potential long survival in multiple myeloma | Q49184612 |
| | Impact of early relapse after auto-SCT for multiple myeloma. | Q53469257 |
| | Multiple Myeloma | Q56453538 |
| | Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone | Q57904548 |
| | Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy | Q58415992 |
| | Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m | Q60203634 |
| | High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial | Q73181635 |
| | Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma | Q74082581 |
| | Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma | Q79407795 |
| | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma | Q80011690 |
| | Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma | Q80764931 |
| | Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial | Q82564216 |
| | Importance of achieving a complete response in multiple myeloma, and the impact of novel agents | Q37729617 |
| | International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma | Q37778947 |
| | Treatment of relapsed and refractory multiple myeloma in the era of novel agents | Q37791639 |
| | Emerging therapies for the treatment of relapsed or refractory multiple myeloma | Q37799862 |
| | Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group | Q37801221 |
| | Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation | Q37829230 |
| | Ultra high-risk myeloma | Q37829258 |
| | Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. | Q37835571 |
| | Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement | Q37835695 |
| | Multiple myeloma treatment strategies with novel agents in 2011: a European perspective | Q37858327 |
| | Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. | Q38463036 |
| | Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression | Q41874321 |
| | The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply). | Q42708667 |
| | Renal insufficiency and failure | Q42757287 |
| | Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p | Q42781523 |
| | Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial | Q42861085 |
| | Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. | Q42921022 |
| | Decitabine versus 5-azacitidine for the treatment of myelodysplastic syndrome: adjusted indirect meta-analysis | Q42922537 |
| | Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies | Q42925566 |
| | Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). | Q42965343 |
| | Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone | Q42971327 |
| | Meeting the unmet needs in anticoagulant therapy | Q43018499 |
| | The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. | Q43018754 |
| | Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study | Q43048164 |
| | Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma | Q43071494 |
| | Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial | Q43109172 |
| | Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma | Q43121688 |
| | Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone | Q43195076 |
| | A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma | Q43251148 |
| | Relapse/Refractory myeloma patient: potential treatment guidelines. | Q43270040 |
| | Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib | Q43280884 |
| | Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma | Q43632773 |
| | Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma | Q43726973 |
| | Transplantation as salvage therapy for high-risk patients with myeloma in relapse | Q44245114 |
| | Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure | Q44620764 |
| | Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. | Q45911819 |
| | Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. | Q46006794 |
| | Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure | Q46094234 |
| | Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). | Q46118120 |
| | Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival | Q46253134 |
| | Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. | Q46573449 |
| | High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe | Q46795068 |
| | Recent major improvement in long-term survival of younger patients with multiple myeloma | Q46977305 |
| | Thalidomide and hematopoietic-cell transplantation for multiple myeloma | Q46981475 |
| | Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial | Q46985882 |
| | Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? | Q48011772 |
| P433 | issue | 1 | |
| P921 | main subject | multiple myeloma | Q467635 |
| P304 | page(s) | 73-85 | |
| P577 | publication date | 2011-10-25 | |
| P1433 | published in | Leukemia | Q6534498 |
| P1476 | title | Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents | |
| P478 | volume | 26 | |